Clinical and laboratory evaluation of children with congenital hyperinsulinism: a single center experience

• Published in: Journal of Pediatric Endocrinology & Metabolism Vol. 36; no. 1; pp. 53 - 57
• Main Authors: Gundogdu, Semra, Ciftci, Mustafa, Atay, Enver, Ayaz, Akif, Ceran, Omer, Atay, Zeynep
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 27.01.2023; Walter de Gruyter GmbH
• Subjects: channel; congenital hyperinsulinism; diazoxide; F-DOPA PET; Hypoglycemia; Laboratories; congenital hyperinsulinism; KATP channel; diazoxide; 18F-DOPA PET
• ISSN: 0334-018X; 2191-0251
• DOI: 10.1515/jpem-2022-0155

To evaluate and present the data regarding clinical, laboratory, radiological and the results of molecular genetic analysis of patients with hyperinsulinemic hypoglycemia in our clinics. A total of 9 patients with CHI followed at Istanbul Medipol University. Data related to gender, age at presentation, birth weight, gestational age, consanguinity, glucose and insulin levels at diagnosis, treatment modalities, response to treatment, the results of genetic analysis and radiological evaluation were gathered from the files. The oldest age at presentation was 6 months. K channel mutation was detected in 55% (n: 5). Diazoxide unresponsiveness was seen in 55% (n: 5). Octreotide was effective in 3 of them. F-DOPA PET performed in 4 diazoxide unresponsive patients revealed focal lesion in 3 of them. Spontaneous remission rate was 66% (n:6). All the patients with normal genetic result achieved spontaneous remission. Spontaneous remission was even noted in diazoxide unresponsive patients and in patients with focal lesion on F-DOPA PET. Clinical presentation of patients with congenital hypereinsulinism is heterogeneous. Spontaneous remission rate is quite high even in patients with severe clinical presentation. It is important to develop methods that can predict which patients will have spontaneous remission. Reporting the clinical and laboratory data of each patient is important and will help to guide the management of patients with hyperinsulinemic hypoglycemia.